Antimicrobial Peptides: A Promising Alternative to Conventional Antimicrobials for Combating Polymicrobial Biofilms

Autor(es):Mostrar menos -

Roque-Borda, Cesar Augusto ; Primo, Laura Maria Duran Gleriani ; Medina-Alarcon, Kaila Petronila ; Campos, Isabella C. ; Nascimento, Camila de Fatima ; Saraiva, Mauro M. S. ; Berchieri, Angelo ; Fusco-Almeida, Ana Marisa ; Mendes-Giannini, Maria Jose Soares ; Perdigao, Joao ; Pavan, Fernando Rogerio ; Albericio, Fernando

• Tipo de documento: Artigo Científico
• Fonte: ADVANCED SCIENCE; v. N/A, p. 29-pg., 2024-11-12.

Resumo

Polymicrobial biofilms adhere to surfaces and enhance pathogen resistance to conventional treatments, significantly contributing to chronic infections in the respiratory tract, oral cavity, chronic wounds, and on medical devices. This review examines antimicrobial peptides (AMPs) as a promising alternative to traditional antibiotics for treating biofilm-associated infections. AMPs, which can be produced as part of the innate immune response or synthesized therapeutically, have broad-spectrum antimicrobial activity, often disrupting microbial cell membranes and causing cell death. Many specifically target negatively charged bacterial membranes, unlike host cell membranes. Research shows AMPs effectively inhibit and disrupt polymicrobial biofilms and can enhance conventional antibiotics' efficacy. Preclinical and clinical research is advancing, with animal studies and clinical trials showing promise against multidrug-resistant bacteria and fungi. Numerous patents indicate increasing interest in AMPs. However, challenges such as peptide stability, potential cytotoxicity, and high production costs must be addressed. Ongoing research focuses on optimizing AMP structures, enhancing stability, and developing cost-effective production methods. In summary, AMPs offer a novel approach to combating biofilm-associated infections, with their unique mechanisms and synergistic potential with existing antibiotics positioning them as promising candidates for future treatments. (AU)

• Processo FAPESP: 23/01664-1 - Síntese e caracterização de análogos do peptídeo antimicrobiano "B1CTcu5" encapsulados em micropartículas colón-específicas e estudos in vitro e in vivo frente ao Mycobacterium tuberculosis
• Beneficiário: Fernando Rogério Pavan
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 21/14603-5 - Descoberta e desenho de fármacos: análogos do peptídeo antimicrobiano B1CTcu5 promissores contra o Mycobacterium tuberculosis
• Beneficiário: Cesar Augusto Roque Borda
• Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Doutorado
• Processo FAPESP: 20/16573-3 - Estudos in vitro e in vivo de análogos do peptídeo antimicrobiano B1CTcu5 encapsulados em micropartículas colón-específicas frente ao Mycobacterium tuberculosis
• Beneficiário: Cesar Augusto Roque Borda
• Modalidade de apoio: Bolsas no Brasil - Doutorado